Loading...
CKPT logo

Checkpoint Therapeutics, Inc.NasdaqCM:CKPT 株式レポート

時価総額 US$356.8m
株価
US$4.26
US$4.45
4.3% 割安 内在価値ディスカウント
1Y127.8%
7D1.7%
1D
ポートフォリオ価値
​
表示

Checkpoint Therapeutics, Inc.

NasdaqCM:CKPT 株式レポート

時価総額：US$356.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Checkpoint Therapeutics（CKPT）株式概要

チェックポイント・セラピューティクス社は、商業段階の免疫療法および標的腫瘍学企業であり、米国内外の固形がん患者に対する新規治療薬の買収、開発、商業化に注力している。 詳細

CKPT ファンダメンタル分析
スノーフレーク・スコア
評価2/6
将来の成長5/6
過去の実績0/6
財務の健全性5/6
配当金0/6

報酬

当社が推定した公正価値より94.7%で取引されている

収益は年間37.66%増加すると予測されています

リスク分析

収益が 100 万ドル未満 ( $41K )

過去1年間で株主の希薄化は大幅に進んだ

US市場と比較して、過去 3 か月間の株価の変動が非常に大きい

過去3か月間に大規模なインサイダー売却が発生


CKPT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Checkpoint Therapeutics, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Checkpoint Therapeutics
過去の株価
現在の株価US$4.26
52週高値US$4.50
52週安値US$1.80
ベータ1.14
1ヶ月の変化3.40%
3ヶ月変化71.08%
1年変化127.81%
3年間の変化-68.91%
5年間の変化-81.23%
IPOからの変化-91.48%

最新ニュース

Recent updates

分析記事 • Sep 20

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 08

Checkpoint: Strong Data, But Comes With Risks

Summary CKPT produced strong data for cosibelimab. However, data was ex-US and from an open-label trial. There's not much cash at CKPT. Checkpoint Therapeutics (CKPT) produced positive results from the registration trial of cosibelimab in skin cancer, however the stock continues to stay depressed from its November highs. What happened in November, why is it still down, and what can make it go back up again - these are the questions. The funny thing here is that nothing really happened in November. I looked at every possible source of data, and apart from a non-relevant earnings release, there doesn't seem to be any particular event or news that led to the spike and the drop around the first week of November. The only thing that came out was the earnings release, on November 4, and like I said, it contains no clues to the price volatility. I checked insider transaction data, and while the insiders here do not ever buy the stock, there are no large sales around November either. I checked another article by a fellow contributor written around that time, and apart from telling us not to worry, they do not shed much illumination on why the stock fell. There wasn't unusual volume either - a sure sign of price volatility - at that time. However, if you look at the charts vis-a-vis the earnings dates, you will see that the stock peaked exactly on earnings release, and then fell drastically. So my best guess is that investors were looking for more clarity on the cosibelimab data release in the earnings press release, which did not happen, leading to the fall. Recall that data was supposed to have been released by end-2021. Speaking of unusual volume, on January 25, ~25 million shares changed hands on that date, against an average volume of 200k odd shares. These were mostly sells. This means, funds must have offloaded their entire stakes that day, the same day when cosibelimab data came out. Such a huge sell-off must have been what kept the stock subdued despite positive trial data. So we do not see a spike even on positive data release - which should be a lesson for biotech investors who play catalyst-driven stocks. The lesson is this: it is naive to think that a catalyst alone will push a stock up. There's a lot of volatility hidden under the murky waters of biopharma investing, and therefore things aren't so predictable here. Coming to the data itself, cosibelimab is an anti-PD-L1 antibody, and it was administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). Key data were: The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4% (95% CI: 36.0, 59.1) based on independent central review of 78 patients using RECIST 1.1 criteria. The median duration of response ((DOR)) had not yet been reached at the data cut-off point (76% of responses are ongoing). Safety data across 201 patients with advanced cancers enrolled and treated in all cohorts remain consistent with those previously reported, with the majority of treatment-emergent adverse events reported as Grade 1 or 2 in severity. Besides metastatic cSCC, the molecule also had an objective response rate (ORR) of 54.8% in 31 patients with locally advanced cSCC. The company presented competitor data in these two indications. The two approved products are Libtayo and Keytruda. The ORR rates from their pivotal trials are quite similar to cosibelimab's data. However, the company has not provided granularity on complete responses besides saying that they are similar to "what's out there," according to Evaluate. 2020 data did show this to be true. Checkpoint's focus is to get into the PD-L1 market with a lower cost drug. Data is also competitive. However, how the FDA will look at it ultimately decides its fate - and they only have an open label phase 1 trial data here, that too outside the US. Recently, Eli Lilly (LLY) and EQRx (EQRX) have tried to bring Chinese PD-L1 inhibitors into the US market, however, the FDA has not been too kind, at least not with Lilly, slamming them for their single country trials. Those are risk factors for Checkpoint, however its trial, although ex-US, was not single-country, having taken place in 9 different countries including France, Spain and Australia. The company also recently wound down the CONTERNO study, a phase 3 study in lung cancer for cosibelimab, citing the Ukraine war as the reason for unsustainably longer enrollment periods. Besides cosibelimab, Checkpoint has a second asset in phase 3 trial - Olafertinib, an anti-EGFR molecule partnered with other companies in Asia. Unlike other EGFRi like Tagrisso® (osimertinib), which have safety issues like
Seeking Alpha • Aug 12

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Checkpoint Therapeutics press release (NASDAQ:CKPT): Q2 GAAP EPS of -$0.16 in-line. Revenue of $0.02M (-87.5% Y/Y) beats by $0.01M. As of June 30, 2022, Checkpoint’s cash and cash equivalents totaled $30.9 million, compared to $41.5 million at March 31, 2022 and $54.7 million at December 31, 2021, a decrease of $10.6 million for the quarter and a decrease of $23.8 million for the first half of 2022. Shares -0.79% PM.
分析記事 • May 18

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patients with cutaneous squamous cell carcinoma. Cosibelimab holds the potential to disrupt the $30 billion PD-(L)1 class of drugs. Cosibelimab is also being developed to treat patients with non-small cell lung cancer, with a global market that is expected to grow to $11.87 billion by 2028.
分析記事 • Feb 15

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 28

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Checkpoint Therapeutics recently announced Cosibelimab hit its primary endpoint with a 47.4% ORR in metastatic cSCC. The company also reported positive safety and tolerability profile. The topline results have encouraged the company to submit a BLA to the FDA later this year. In addition, the company is planning on filing for approval in the EU. If approved, Cosibelimab has a unique profile and competitive pricing that could make it a serious contender in a growing immunotherapy market. The announcement triggered a disappointing spike in the share price. I suspect the market is waiting for additional data and perhaps approval in hand before fully committing to CKPT. I believe the lackluster response to the data has produced a buying opportunity.
Seeking Alpha • Nov 26

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch in 2023. Volatility has the share price, which is making big moves in both directions as we move closer to year-end. Investors need to have a game plan. I believe the recent pullback could be a great opportunity for me to buy ahead of this incredibly potent catalyst.
分析記事 • Oct 30

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jul 17

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 14

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

Checkpoint Therapeutics expects to report Cosibelimab’s top-line data in Q4 of this year. The company anticipates submitting a BLA and MMA next year with a potential launch in 2023. I have pushed CKPT aside several times, but I can no longer ignore its potential upside from Cosibelimab and its potential to disrupt a $25B+ checkpoint market. I review some of Cosibelimab’s data and match it up to some of the market’s leading PD-1 and PD-L1 agents. I reveal my investment strategy and long-term outlook.
Seeking Alpha • Jun 21

Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

The following slide deck was published by Checkpoint Therapeutics, Inc. in conjunction with this event.

株主還元

CKPTUS BiotechsUS 市場
7D1.7%1.2%1.0%
1Y127.8%34.9%28.7%

業界別リターン: CKPT過去 1 年間で34.9 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: CKPT過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。

価格変動

Is CKPT's price volatile compared to industry and market?
CKPT volatility
CKPT Average Weekly Movement17.7%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: CKPTの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: CKPTの 週次ボラティリティ は、過去 1 年間で12%から18%に増加しました。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
201424James Olivierocheckpointtx.com

チェックポイント・セラピューティクス社は、商業段階の免疫療法および標的腫瘍学企業であり、米国内外の固形腫瘍がん患者に対する新規治療法の獲得、開発、商業化に注力している。同社の主要な抗体製品候補はUNLOXCYTで、特定の再発・転移性がん患者を対象とした第1相臨床試験中であり、CK-302は血液悪性腫瘍および固形がんを対象とした前臨床試験中の製品候補である。また、成人の転移性非小細胞肺がん患者を対象とした第3相臨床試験中のオラフェルティニブ、様々な進行・転移性固形がんを対象としたCK-103、CAIX発現細胞を認識し、抗体依存性細胞傷害性および補体依存性細胞傷害性により細胞を死滅させる前臨床試験中の製品候補である抗炭酸脱水酵素IX（CAIX）抗体も開発中である。また、コシベリマブの開発に関してAdimab, LLCと、オラフェルチニブの開発・商業化に関してNeuPharma, Inc.と、BETブロモドメインを阻害する新規化合物の開発・商業化に関してJubilant Biosys Limitedとライセンス契約および提携契約を結んでいるほか、ダナファーバー癌研究所（Dana-Farber Cancer Institute, Inc.チェックポイント・セラピューティクス社は2014年に法人化され、マサチューセッツ州ウォルサムを拠点としている。

Checkpoint Therapeutics, Inc. 基礎のまとめ

Checkpoint Therapeutics の収益と売上を時価総額と比較するとどうか。
CKPT 基礎統計学
時価総額US$356.83m
収益（TTM）-US$56.51m
売上高(TTM)US$41.00k
8,703x
P/Sレシオ
-6.3x
PER（株価収益率

CKPT は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
CKPT 損益計算書（TTM）
収益US$41.00k
売上原価US$31.44m
売上総利益-US$31.40m
その他の費用US$25.11m
収益-US$56.51m

直近の収益報告

Mar 31, 2025

次回決算日

該当なし

一株当たり利益（EPS）-0.67
グロス・マージン-76,590.24%
純利益率-137,821.95%
有利子負債／自己資本比率0%

CKPT の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/06/03 21:57
終値2025/05/29 00:00
収益2025/03/31
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Checkpoint Therapeutics, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3

アナリスト機関
Mayank MamtaniB. Riley Securities, Inc.
Justin WalshB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.